Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 63,712Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Fiasp

02 5NovoMix

03 1NovoMix/NovoLog Mix

04 5NovoRapid

05 1NovoRapid/NovoLog

06 2Novomix/Novolog Mix

07 2Novorapid/Novolog

08 5Ryzodeg

PharmaCompass

01

Brand Name : NovoMix

Biphasic Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : NovoMix

arrow
2024 ACI Convention
Not Confirmed

Biphasic Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,567

2019 Revenue in Millions : 1,559

Growth (%) : 1

blank

02

Brand Name : NovoRapid

Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : NovoRapid

arrow
2024 ACI Convention
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 2,753

2019 Revenue in Millions : 2,937

Growth (%) : -6

blank

03

Brand Name : Ryzodeg

Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ryzodeg

arrow
2024 ACI Convention
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 210

2019 Revenue in Millions : 162

Growth (%) : 30

blank

04

Brand Name : Fiasp

Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fiasp

arrow
2024 ACI Convention
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 225

2019 Revenue in Millions : 202

Growth (%) : 11

blank

05

Brand Name : Fiasp

Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fiasp

arrow
2024 ACI Convention
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 266

2020 Revenue in Millions : 222

Growth (%) : 26

blank

06

Brand Name : NovoMix

Biphasic Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : NovoMix

arrow
2024 ACI Convention
Not Confirmed

Biphasic Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 1,447

2020 Revenue in Millions : 1,541

Growth (%) : -1

blank

07

Brand Name : NovoRapid

Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : NovoRapid

arrow
2024 ACI Convention
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 2,429

2020 Revenue in Millions : 2,708

Growth (%) : -6

blank

08

Brand Name : Ryzodeg

IInsulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ryzodeg

arrow
2024 ACI Convention
Not Confirmed

IInsulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 261

2020 Revenue in Millions : 207

Growth (%) : 33

blank

09

Brand Name : NovoRapid

Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : NovoRapid

arrow
2024 ACI Convention
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 2,255

2021 Revenue in Millions : 2,429

Growth (%) : -7

blank

10

Brand Name : Ryzodeg

Insulin Aspart

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Ryzodeg

arrow
2024 ACI Convention
Not Confirmed

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 421

2021 Revenue in Millions : 261

Growth (%) : 62

blank